Drug Trial Radar · NCT07758673
Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Apr 17, 2027
Primary completion
Jul 26, 2028
Study completion Jul 26, 2028
Sponsor
- Lead sponsor
- City of Hope Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Aug 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial tests the safety and side effects of B-cell activating factor receptor (BAFFR) chimeric antigen receptor (CAR) T cells and how well they work in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoblastic lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). CAR T-cell therapy, such as BAFFR-CAR T cells, is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving BAFFR-CAR T cells may be safe, tolerable and/or effective in treating patients with relapsed or refractory B-cell ALL and B-cell lymphoblastic lymphoma.
Conditions
- Recurrent B Acute Lymphoblastic Leukemia
- Recurrent B Lymphoblastic Lymphoma
- Refractory B Acute Lymphoblastic Leukemia
- Refractory B Lymphoblastic Lymphoma
Interventions
Autologous BAFFR-targeting CAR T CellsBiological
Given IV
Biospecimen CollectionProcedure
Undergo blood and CSF specimen collection
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration and biopsy
Bone Marrow BiopsyProcedure
Undergo bone marrow aspiration and biopsy
Bridge TherapyProcedure
Receive bridging therapy
Chest RadiographyProcedure
Undergo chest x-ray
Computed TomographyProcedure
Undergo CT or PET/CT
CyclophosphamideDrug
Given IV
Echocardiography TestProcedure
Undergo ECHO
FludarabineDrug
Given IV
LeukapheresisProcedure
Undergo leukapheresis
Magnetic Resonance ImagingProcedure
Undergo brain MRI
Multigated Acquisition ScanProcedure
Undergo MUGA
Positron Emission TomographyProcedure
Undergo PET/CT
Ultrasonographic ElastographyProcedure
Undergo liver ultrasonographic elastography
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: Up to 28 days after chimeric antigen receptor (CAR) T cells
- Dose-limiting toxicityTime frame: From the start of CAR T infusion up to 28 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California · Recruiting
City of Hope at Irvine Lennar
Irvine, California · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.